Bexis was updating the chapter of his drug and medical device treatise pertaining to, inter alia, punitive damages and came across In re Valsartan, Losartan, & Irbesartan Products Liability Litigation, 2020 WL 8970347 (D.N.J. March 12, 2020).
Consistent with a number of alarmingly pro-plaintiff decisions that we’ve already seen from that MDL,